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Background: We recently developed a clinical decision support tool, capable of estimating the likelihood of survival at
3 and 12 months following surgery for patients with operable skeletal metastases. After making it publicly available on
www.PATHFx.org, we attempted to externally validate it using independent, international data.
Methods: We collected data from patients treated at 13 Italian orthopaedic oncology referral centers between 2010
and 2013, then applied to PATHFx, which generated a probability of survival at three and 12-months for each patient.
We assessed accuracy using the area under the receiver-operating characteristic curve (AUC), clinical utility using
Decision Curve Analysis (DCA), and compared the Italian patient data to the training set (United States) and first
external validation set (Scandinavia).
Results: The Italian dataset contained 287 records with at least 12 months follow-up information. The AUCs for
the three-month and 12-month estimates was 0.80 and 0.77, respectively. There were missing data, including the
surgeon’s estimate of survival that was missing in the majority of records. Physiologically, Italian patients were similar to
patients in the training and first validation sets. However notable differences were observed in the proportion of those
surviving three and 12-months, suggesting differences in referral patterns and perhaps indications for surgery.
Conclusions: PATHFx was successfully validated in an Italian dataset containing missing data. This study demonstrates
its broad applicability to European patients, even in centers with differing treatment philosophies from those previously
studied.
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Estimating survival in patients with skeletal metastases
is important to set patient and physician expectations, as
well as to guide surgical decision making [1–4]. During
the preoperative evaluation, survival estimates can help
surgeons carefully avoid under- or overtreatment of the
disease by identifying which patients are likely to benefit
from surgery but also whether a more durable implant
may be necessary [5, 6]. Though most physicians are able
to derive subjective survival estimates, they are generally
inaccurate, and treating surgeons may be uncomfortable
recording them in the medical record, or communicating
them directly to patients [7].
With this in mind, we developed a Bayesian Belief
Network capable of estimating three and twelve month
survival in patients undergoing surgery for skeletal me-
tastases [8]. It is intended to guide, not replace, good
clinical judgment and uses prognostic variables previ-
ously demonstrated to risk stratify these patients, includ-
ing the oncologic diagnosis [8, 9], the extent of disease
[10], the patient’s performance status [11], and basic la-
boratory assessments [12]. In addition to delivering the
likelihood of survival, PATHFx also estimates the quality of
evidence supporting that estimation, which can be used by
the treating surgeon to qualify each estimate. Following its
development, we ensured that the tool was suitable for
the clinical setting by performing decision curve analysis
[13, 14], externally validated it using Scandinavian registry
data [15], and made it publicly available to the international
community, without charge, on www.PATHFx.org. How-
ever, the success of this tool depends on its performance in
a variety of cultures, patient populations and institutions
that may have differing treatment philosophies from those
previously studied. In addition, though PATHFx was de-
signed using the records of patients with metastases of the
appendicular and axial skeleton, the first external validation
set lacked patients treated for axial lesions. As such, add-
itional validation studies are needed that include patients
with both appendicular and axial metastases.
The purpose of this study was to (1) externally validate
the PATHFx tool in an Italian patient population by
evaluating accuracy by ROC analysis and clinical utility
using DCA, and (2) compare the distributions of pa-
tients to both the training set (U.S.) and first external
validation (Scandinavian) datasets, respectively.
Methods
Data collection
The Italian Society of Orthopaedic and Traumatology
(SIOT) established the Bone Metastasis Study Group in
order to study patients with bone metastases and im-
prove treatment. In the current study we retrospectively
reviewed the records of 287 patients from 2010 to 2013
treated at one of thirteen Italian referral centers. Eachrecord contained the 17 demographic and clinical variables,
required of the PATHFx models. Survival was defined as
the time elapsed from the date of surgery to the date of
death or last follow-up. All records had sufficient follow-up
to establish 12-month survival. This study received local
ethical approval from the Università Campus Bio-Medico
di Roma (Prot:15/13 19 June 2013). Informed consent was
not required prior to using de-identified registry data.
Though data was collected from multiple Italian cen-
ters, the indications for surgery were standardized. In
general, patients with metastatic disease of the extrem-
ities were offered surgery to prevent or treat a pathologic
fracture, according to the Mirel’s criteria [16]. The surgical
indications for spine metastasis were: intractable pain, the
onset of neurological deficits, caused by the compression
of the myeloradicular structures of the neoplastic mass or
by a pathological fracture of the vertebra, the mechanical
instability of the spinal segment affected by the metastasis
that causes a disabling mechanical pain and/or a neuro-
logical deficit and a failure of the previous therapy [17].
The PATHFx models are Bayesian Belief Networks
comprised of ten prognostic features [8]. These include:
age at the time of surgery, sex, indication for surgery
(impending or completed pathologic fracture), number
of bone metastases (solitary or multiple), surgeon’s esti-
mate of survival (postoperatively, in months), presence
or absence of visceral metastases, presence or absence of
lymph node metastases, preoperative hemoglobin concen-
tration (g/dL, on admission to the hospital, prior to trans-
fusion, if applicable), absolute lymphocyte count (K/μL),
and the patient’s primary oncologic diagnosis, classified
into one of three groups as previously described [8]. For
example, lung, gastric, and hepatocellular carcinoma and
melanoma were assigned to Group 1; sarcomas and other
carcinomas, Group 2; and breast, prostate, renal cell, and
thyroid carcinoma, multiple myeloma, and malignant
lymphoma, Group 3.
The definitions used for this study were similar to
those previously described [15]. Briefly, an impending
pathologic fracture was one in which the degree of bone
and/or cortical disruption warranted, in the opinion of
the treating surgeon, prophylactic surgical stabilization
to prevent fracture. Lesions that resulted in a change in
bone length, alignment, rotation, or loss of height as de-
termined by imaging, were considered completed patho-
logic fractures. Biopsy-proven and/or clinically obvious
metastases to organs within the chest, abdomen or brain
were considered visceral metastases. Only biopsy-proven
metastases to the lymph nodes were considered indica-
tive of lymph node involvement.
External validation
Using commercially available software (FasterAnalytics,
DecisionQ Corp., Washington, DC, USA), we applied data
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which estimated the likelihood of postoperative survival at
three and 12 months, for each record. We then performed
Receiver-operating characteristic (ROC) curve analysis
and calculated the area under the ROC curve (AUC) as a
measure of accuracy. The models were used “as-is” and
were not re-fit or otherwise improved using either the
Scandinavian or Italian validation sets. Bayesian Belief
Networks retain functionality in the presence of missing
data so no other imputation methods were employed. Val-
idation was considered successful if the AUC was greater
than 0.70 and was determined a priori. We chose this
threshold because the authors consider it to be the lowest
acceptable limit, however, Decision Curve Analysis (DCA)
[13] was performed to determine whether the models
should be used clinically.
The characteristics of the Italian set were compared to
those of the training set and first external validation set.
Continuous variables were tabulated and presented as
mean (standard deviation), median (interquartile range)
and categorical variables as number (%) (Table 1). The
distribution of each continuous variable was compared with
the normal distribution using the Shapiro-Wilk test.
Equality of variance for continuous variables was deter-
mined using the Brown-Forsythe and Levene test. Statis-
tical differences between continuous variables versus the
bivariate outcome variables were evaluated using the
Mann–Whitney U-test and the post hoc Tukey-KramerTable 1 Comparison of continuous features for training (U.S.), first v
Training set n = 189 Scandinavian se
Feature %
Age at surgery (years)b Mean 62.4 66.3 0
SD 13.7 12.8
Median 62.7 67
IQR 54.4, 72.2 58, 76
Hemoglobin concentration
(mg/dL) a,b
Mean 11.5 11.5 0.6
SD 1.9 3.5
Median 11.4 11.3
IQR 10.1, 12.9 10.3, 12.6
Absolute lymphocyte count
(K/μL)a,b
Mean 1.2 1.2 83
SD 1.3 0.74
Median 1.0 1.2
IQR 0.6, 1.5 0.8, 1.6
Senior surgeon’s estimate of
survival (months)a,b
Mean 10.3 N/A 10
SD 8.6
Median 6.0
IQR 4.0, 12.0
SD standard deviation, IQR interquartile range, N/A not applicable
*Distributions are significantly different between training and validation sets by two
aDenotes feature of 3-month model
bDenotes feature of 12-month modelassessment. Categorical variables were also tabulated
and associations compared using Fisher’s exact test or
chi-square analysis, depending on the number of ex-
pected values in the contingency matrix. A two-tailed α
of 0.05 was considered statistically significant. We used
JMP® Version 9.0.2 (SAS Institute, Inc, Cary, NC, USA) and
R© Version 3.0.2 (R Foundation for Statistical Computing,
Vienna, Austria) for all statistical estimations.Results
Two-hundred eighty seven (287) records had adequate
follow-up information to establish survival at 3 and
12 months postoperatively and thus comprised the valid-
ation set. None of these records were excluded.
PATHFx correctly classified three-month survival in
253 of 287 (88 %) patients, and 12-month survival in
199 of 287 (69 %) patients. On ROC curve analysis, the
AUCs were 0.80 and 0.77, respectively, for the three and
12-month survival, respectively.
Decision analysis revealed that PATHFx should be
used, rather than assume all patients or no patients
would ultimately survive longer than 12 months. How-
ever, since 93 % of Italian patients survived longer than
three months, DCA indicated that outcomes may be bet-
ter if orthopaedic surgeons assumed all patients would
survive three months, rather than use the three month
model (Fig. 1).alidation (Scandinavian) and second validation (Italian) datasets
t n = 815 Italian set n = 287
missing % missing vs. Training set p vs. Scandinavian set p
63.1 0 0.54 <0.005*
11.7
64
56, 72
11.5 10 0.83 0.90
1.4
12
11,13
.8 1.3 23 0.59 0.40
0.50
1.5
1.0, 2.0
0 11.2 87 0.56 N/A
7.0
10
5, 20
-tailed Student’s t-test
Fig. 1 These decision curves depict the net benefit of the three-month (a) and 12-month (b) models, when applied to the Italian external validation
set. Net benefit is defined as a three- or 12-month survivor who duly undergoes surgery, or receives an implant commensurate with his/her estimated
survival. It is important to note that nearly all (93 %) patients referred for orthopaedic intervention survived longer than three months and 63 %
survived longer than one year, representing the theoretical maximum net benefit for a and b, respectively. As a result, a indicates that one
could achieve better outcomes by assuming all patients will survive greater than 3 months rather than using the three-month model. This
analysis highlights the importance of decision analysis, even for relatively accurate models such as this one, with an AUC of 0.80. b indicates
that the 12-month model should be used, rather than assume all patients, or none of the patients will survive greater than 12 months
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patients in the validation set differed from those of pa-
tients in the U.S. training set. Several features differed
significantly (p < 0.05) including, presence of visceral and
lymph node metastases, number of bone metastases,
and three and 12-month survival. Nonsignificant differ-
ences were observed in age at surgery, gender, preopera-
tive hemoglobin concentration, absolute lymphocyte
count, oncologic diagnosis grouping, pathologic fracture
status, ECOG performance status, and the surgeon’s esti-
mate of survival. When compared to the Scandinavian
set, most features differed significantly (p < 0.05) with
the exception of gender, preoperative hemoglobin con-
centration, absolute lymphocyte count and the presence of
visceral metastases. Most features in the validation set had
some degree of missing data, also summarized in Tables 1
and 2. Notable features included the surgeon’s estimate of
survival (missing in 87 %), absolute lymphocyte count
(missing in 23 %), and ECOG performance (missing in
20 %), all of which are important first- or second-degree
predictors of survival in the PATHFx tool.Discussion
We successfully externally validated PATHFx in an Ital-
ian patient population including patients with both axial
and appendicular metastases. In doing so, we confirm
the model’s ability to estimate the likelihood of survival
at two time points useful for orthopaedic surgical
decision-making. This is the second external validationstudy and demonstrates the model is also generalizable
to the Italian patient population.
When one considers the goals of treating patients with
skeletal metastases are to relieve pain and to restore
function for the maximum amount of time, careful esti-
mates of survival, such as those provided by PATHFx, are
necessary to avoid over- or undertreatment of the disease.
For example, if a surgeon considers nonoperative treat-
ment, a very low probability of survival at three months
may support this decision. By extension, if a surgeon were
to consider using a less invasive and less durable implant
such as an intramedullary nail, longer estimates of survival
such as 3–12 months would support this decision. Con-
versely, estimates of survival greater than one year may
support the decision to use a more durable implant such
as a prosthesis in the case of extremity tumors, or more
complicated spine procedures including vertebrectomies
and combined anterior and posterior techniques. In fact,
this study represents the first external validation of
PATHFx in patients with axial (n = 34, 12 %), as well as ap-
pendicular skeletal metastases. This is important because
although the training set contained 33 (18 %) spine pa-
tients, the Scandinavian external validation set contained
only patients with extremity metastases.
Though there are several prognostic scoring systems
designed for spine patients [10, 11, 18], none provide the
surgeon with an estimation of the likelihood of survival
at three and 12 months, which the authors consider to
be useful for surgical decision-making. In addition, a re-
cent analysis of seven prognostic tools demonstrated the
Table 2 Comparison of categorical features for training (U.S.), first validation (Scandinavian) and second validation (Italian) datasets
Feature Training set n = 189 Scandinavian set n = 815 Italian set n = 287
No. % No. % % missing No. % % missing vs. training set p vs. Scandinavian set p
Gender male 85 45.0 369 45.3 0 120 42 0 0.50 0.31
female 104 55.0 446 54.7 167 58
Oncologic diagnosis
grouping
1.0 52 27.3 173 21.3 0.4 63 23 2 0.42 0.007*
2.0 34 18.2 74 9.2 44 16
3.0 103 54.5 567 69.1 173 62
Organ metastases yes 114 60.3 325 39.8 6.3 91 36 12 0.0001* 0.08
no 75 39.7 441 53.9 161 64
Lymph node metastases yes 36 18.8 169 20.8 61.6 96 40 16 0.0001* 0.0007*
no 153 81.2 143 17.6 146 60
Skeletal metastases solitary 55 29.0 123 15.2 3.4 139 49 1 0.0001* 0.0001*
multiple 134 71.0 666 81.4 144 51
Pathologic fracture status yes 84 44.2 614 75 0.9 143 52 5 0.08 0.0001*
no 105 55.8 196 24.1 131 48
ECOG performance status 0,1,2 93 49.2 558 68.3 0 123 54 20 0.39 0.0001*
3,4 96 50.8 257 31.7 106 46
Survival >3 months yes 129 68.3 557 68.2 0 267 93 0 0.0001* 0.0001*
no 60 31.7 258 31.8 20 7
Survival >12 months yes 79 41.8 241 29.8 0 181 63 0 0.0001* 0.0001*
no 110 58.2 574 70.2 106 37
Abbreviations: ECOG Eastern Cooperative Oncology Group, % missing, the proportion of unknown or missing data within the validation set
*Proportions are significantly different between training and validation sets by Chi-square method
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PATHFx codifies the presence of visceral metastases,
number of skeletal metastases and diagnosis grouping,
which are all used by the modified Bauer method, and
may explain why both models function accurately, in this
setting. Nevertheless, it may be important to consider
neurologic impairment in patients with spine metastases,
as recommended by Tokuhashi [11]. However, ECOG per-
formance status which is also used by PATHFx may be an
acceptable surrogate, since it is prognostic in patients with
both axial [11] and appendicular metastases [8] notwith-
standing the obvious differences in impairment due to
neurologic as opposed to end-stage metastatic bone in-
volvement. Still, we recognize the importance of a tool
useful in the treatment of all patients with skeletal metas-
tases—not simply those with spine or appendicular in-
volvement. As such, the performance or applicability of
PATHFx in the present validation set is encouraging.
PATHFx performed well in the Italian patient popula-
tion, despite significant differences when compared to the
training and previous validation sets (Tables 1 and 2). Im-
portantly, 93 % of Italian patients survived longer than
3 months, which is much higher than either of the two
previously studied groups. This may represent a key dif-
ference in the Italian patients, or more likely treatmentphilosophy and patient selection when compared to the
U.S. and Scandinavian centers.
In addition, 63 % of Italian patients survived more than
12 months. This is twice as many as in the Scandinavian
validation set, and nearly twice that observed in the training
set. This, too may indicate key differences in patient selec-
tion and is surprising since there was a similar proportions
of patients with pathologic fractures (p = 0.08), more-
favorable diagnosis group (Group 3) (p = 0.42) and good
performance status (ECOG 0,1,2) (p = 0.39) when com-
pared to the training set. Still this may be explained by re-
ferral patterns among the Italian centers. Italian oncologists
typically refer patients with excellent prognoses for ortho-
paedic consultation. In patients with more extensive disease
and less favorable prognoses, however, surgery may be
deemed unsuitable in the eyes of the oncologist, which ob-
viates the need for an orthopaedic opinion. However, this
practice may exclude patients that may benefit from less in-
vasive stabilization or palliative procedures [20–22].
Nearly half of Italian patients included in this study
presented with a solitary skeletal metastasis. This was
unexpected, given that this proportion is much higher
than both the training and previous validation sets, and
could represent more effective disease surveillance prac-
tices than those in Scandinavia or the U.S. However,
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is more likely that Italian patients with less favorable prog-
noses—especially in the setting of impending pathologic
fractures—were not referred for surgical management.
The accuracy for the three and 12-month models was
0.80 and 0.77, respectively. When compared to the original
cross-validation AUCs of 0.86 and 0.83 [8], this represents
a non-trivial, but acceptable 0.06-point degradation in
model accuracy and is similar to that observed following
external validation in the Scandinavian set (0.79 and 0.76,
respectively) [15]. Still by maintaining accuracy in differing
patient populations, we believe PATHFx is sufficiently ro-
bust, and DCA suggests it may be used clinically, while
undergoing additional external validation in more diverse
patient populations.
The PATHFx models were designed to help surgeons
avoid overtreatment or undertreatment of skeletal me-
tastases. Previous work demonstrated that the models
were suitable for clinical use, and that overly optimistic
or pessimistic estimates generated by PATHFx were of
unequal clinical significance [14]. This is perhaps most
important in the three month model that was designed
to help surgeons identify which patients may benefit
from a surgical or nonsurgical course of treatment. The
present study demonstrated 34 (12 %) of records were
misclassified by the three-month model. Of these, sur-
vival was overestimated in 13 (5 %) records, representing
the maximum number of potentially unnecessary surger-
ies performed at the end of life. However, this estimate
should be considered the theoretical maximum, since it
likely includes patients who met surgical criteria and
died of complications unrelated to the progression of
disease. These results are more accurate than those ob-
served in the Scandinavian set in which three month
survival was overestimated in 15 % of records [15] and
may be due to the larger proportion of Italian patients
who survived greater than three months. If we consider
that between 6 and 23 % of patients die within six weeks
of surgery [23–25], then the clinical impact of such over-
estimates may fall within the acceptable norm.
Though one may consider an AUC of 0.8 for the
three-month model to be sufficiently accurate, decision
analysis helps illustrate the clinical impact of applying
the model to a population in which virtually every pa-
tient referred for orthopaedic management of metastatic
bone disease survives three months. Following DCA, we
observe that at threshold probabilities (the point at
which surgeons become indecisive about whether to
offer surgery) less than 15 %, the model is equivalent to
one in which all patients are expected to survive greater
than three months. At thresholds >90 %, the three-
month model should result in better outcomes. How-
ever, at thresholds between 15 and 90 %, an Italian
orthopaedic surgeon is better off treating patients as ifall will survive more than three-months, rather than use
the three-month model. In the latter case, an erroneous
underestimate may prompt the surgeon to withhold sur-
gery from one in ten patients in whom it was otherwise
indicated.
By extension, the 12-month model was designed to sup-
port decisions surrounding the type of procedure, as well
as implant durability required for each patient. Of the 88
records misclassified by the 12-month model, survival was
underestimated in 44 (15 %) cases. This represents the
theoretical maximum proportion of patients at risk for im-
plant failure if a less durable implant were used. This is
higher than that observed in the Scandinavian validation
set [15], in which 12-month survival was underestimated
in 7.6 % of records. Though long term follow-up data were
not available for this study beyond 12 months, we expect
the proportion of patients surviving greater than 24 and
36 months, to decrease considerably. This trend has been
observed previously [6, 8, 15], and further decreases the
theoretical number of implants at risk, over time.
One of the most salient features of PATHFx is the ability
to function in the presence of missing data. This attribute
is particularly important when considering the surgeon’s
estimate of survival was missing in 87 % of Italian and
100 % of Scandinavian records. The models maintained
their accuracy because BBNs encode the information con-
tained within the surgeon’s estimate in terms of shared,
probabilistic relationships with other features, allowing
one to “export” palliative expertise into settings where it
may not exist. Though caution should be used when en-
tering the surgeon’s estimate, those who are unsure of
their estimate—or experience level—may simply leave it
blank. Doing so will maintain accuracy of the model, while
not introducing undue bias.
This study has several limitations. First, we developed
PATHFx using the records of patients who underwent
orthopaedic surgery for their skeletal metastases. Thus, it
may not be applicable to all patients with metastatic dis-
ease, especially those in who are treated non-operatively.
Second, similar to the previous Scandinavian external val-
idation set, the Italian patient population was relatively
homogeneous. However, we sought to obtain a repre-
sentative sampling of Italian patients by collecting data
from thirteen centers. Additionally, it is possible that
PATHFx may become more accurate, by including other
features potentially associated with survival in this patient
population such as alkaline phosphatase [26], N-telopeptide
[27, 28], and C-Reactive protein [29], or the degree of
neurologic impairment as suggested by Tokuhashi. In
addition, the time points chosen for PATHFx (three and
12-months) were initially chosen by two of the authors
(JAF and JHH) because they are useful for orthopaedic sur-
gical decision-making. Based on a recent study of practice
patterns [30], other time points such as one-month and
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and 12-month estimates to help surgeons decide on an op-
erative strategy. One and six-month models are currently
under development and would allow for a direct compari-
son with existing tools to estimate survival in patients with
axial metastases, such as the Tokuhashi method [11]. Next,
the degree of experience required by surgeons to provide
useful, as opposed to confounding, surgeon’s estimates is
under further study, as the present study is too small to de-
rive any meaningful information. Finally, PATHFx is a clin-
ical decision support tool and should not supplant good
clinical judgment by the treating surgeon and clinical team.
Palliative surgery, by definition, can be appropriate even in
patients with very short life expectancies, and low estimates
of survival generated by any prognostic tool should not be
used to deny these types of interventions if otherwise clinic-
ally indicated.
Conclusions
In conclusion, we successfully validated PATHFx using
an Italian dataset containing patients with axial and ap-
pendicular skeletal metastases. This is the second exter-
nal validation study and demonstrates that the tool is
suited for clinical use in Italy. However, the three-month
model should be used with caution in an Italian popula-
tion, wherein nearly all (93 %) of patients referred for
orthopaedic management of skeletal metastases are
likely to survive longer than three months. Prospective,
multicenter validation is necessary to confirm utility in
other diverse patient populations and clinical settings,
over time, which will provide an opportunity to assess
whether the addition of newer, potentially prognostic
variables could increase accuracy.
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